人民财讯8月27日电，华恒生物(688639)8月27日晚间披露半年报，2025年上半年，公司实现营业收入 14.89亿元，同比增长46.54%；归属于上市公司股东的净利润1.15亿元，同比下降23.26%；基本每股收 益0.46元。 ...

Core Viewpoint - Anhui Huaheng Biotechnology Co., Ltd. reported significant growth in revenue but a decline in net profit for the first half of 2025, indicating challenges in maintaining profitability despite increased sales [2][3]. Company Overview and Financial Indicators - The company achieved operating revenue of approximately 1.49 billion RMB, a 46.54% increase compared to the same period last year [3]. - Total profit decreased by 27.92% to approximately 118.57 million RMB, while net profit attributable to shareholders fell by 23.26% to about 114.89 million RMB [3]. - The company's total assets increased by 6.26% to approximately 5.30 billion RMB, and net assets rose by 2.53% to about 2.63 billion RMB [3]. Industry and Business Development - The company operates in the biotechnology manufacturing sector, focusing on bio-based products, particularly amino acids and vitamins, which are increasingly in demand due to trends in sustainable agriculture and animal nutrition [4][5]. - The global shift towards bio-manufacturing is expected to result in 35% of chemicals and industrial products being derived from biological processes by 2030, highlighting the industry's growth potential [6]. - The company has established itself as a leading manufacturer of bio-based products, with a diverse product range including amino acids, vitamins, and bio-based materials [8]. Market Conditions - The demand for amino acids is projected to grow due to the promotion of precision nutrition in animal feed, which aims to reduce reliance on traditional feed ingredients like soybean meal [5]. - The vitamin market is also evolving, with advancements in synthetic biology and metabolic engineering expected to reshape production processes and enhance efficiency [6]. - Bio-based materials are gaining traction as they offer lower greenhouse gas emissions compared to fossil-based materials, positioning the company favorably in a rapidly growing market [7]. Operational Strategies - The company is enhancing its product resource allocation and investing in new product development to improve profitability and market competitiveness [8]. - It is deepening its international development strategy by collaborating with global industry leaders and optimizing production processes to reduce energy consumption and environmental impact [9][10]. - The establishment of an AI digital laboratory aims to integrate AI technology into the company's operations, enhancing research and development capabilities [10]. Core Competencies - The company has developed two major technology platforms for fermentation and enzyme methods, achieving significant breakthroughs in the large-scale production of L-alanine and L-valine [12][13]. - It maintains strong partnerships with major clients, including Fortune 500 companies, which helps the company stay attuned to market demands and technological advancements [12]. - The focus on sustainable practices and the use of renewable resources in production processes align with global trends towards green manufacturing [13].

Company Overview - Anhui Huaheng Biotechnology Co., Ltd. is listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board with the stock code 688639 [2] - The company reported total assets of approximately 5.30 billion RMB at the end of the reporting period, reflecting a 6.26% increase from the previous year [2] Financial Performance - The company's operating revenue for the reporting period reached approximately 1.49 billion RMB, marking a significant increase of 46.54% compared to the same period last year [2] - Total profit for the period was approximately 118.57 million RMB, which represents a decrease of 27.92% from the previous year [2] - The net profit attributable to shareholders of the listed company was approximately 114.76 million RMB, down 22.20% year-on-year [2] Shareholder Information - As of the end of the reporting period, the total number of shareholders was 8,247 [3] - The largest shareholder, Guo Henghua, holds 18.08% of the shares, amounting to 45,227,285 shares [3] - Other significant shareholders include Ningbo Ruiheyuan Venture Capital with 7.77% and China Agricultural Bank with 3.26% [3] Important Matters - The report indicates that there were no significant changes in the company's operating conditions during the reporting period [6]

证券代码：688639 证券简称：华恒生物 公告编号：2025-032 安徽华恒生物科技股份有限公司 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的 《2025 年半年度报告》《2025 年半年度报告摘要》。 安徽华恒生物科技股份有限公司（以下简称"公司"）第四届监事会第十七 次会议于 2025 年 8 月 27 日在公司会议室以现场结合通讯方式召开。本次会议应 到监事 3 人，实到监事 3 人。会议通知已于 2025 年 8 月 15 日以专人递送方式送 达全体监事。会议由监事会主席刘洋召集和主持。本次会议的召集、召开符合《中 华人民共和国公司法》和《公司章程》的有关规定。 二、监事会会议审议情况 经与会监事审议，议案表决结果如下： （一） 审议通过《关于公司 2025 年半年度报告及摘要的议案》 监事会认为：公司 2025 年半年度报告及其摘要内容真实、准确、完整，无 虚假记载、误导性陈述或者重大遗漏，2025 年半年度报告及其摘要的编制、审 核以及董事会的审议程序符合法律法规、公司章程等相关规定，内容与格式符合 相关规定，公允地反映了公司 2025 年半年度的财务状况和经 ...

Fundraising Overview - The total amount raised from the initial public offering (IPO) in 2021 was RMB 62,532 million, with a net amount of RMB 55,925.88 million after deducting issuance costs of RMB 6,606.12 million [1][3] - As of June 30, 2025, the total amount of funds raised from the IPO was RMB 58,997.34 million, with various deductions leading to an actual investment amount of RMB 55,925.88 million [2][3] Fund Utilization - By June 30, 2025, the actual investment amount from the 2021 IPO was RMB 45,692.77 million, with specific allocations detailed in the report [8][9] - The company approved the use of surplus funds from the "Fermentation Method L-Alanine 5000 tons/year technical transformation and expansion project" and "Alternate annual production of 25,000 tons of L-Alanine and L-Valine project" to permanently supplement working capital [3][9] 2022 Fundraising - In 2022, the company raised RMB 699,999,981.40 through a targeted issuance of A-shares, with a net amount of RMB 68,380.91 million after deducting issuance costs of RMB 1,619.09 million [4][5] - As of June 30, 2025, the total investment from the 2022 fundraising was RMB 68,404.964 million, with specific allocations also detailed in the report [8][12] Fund Management - The company has established a fundraising management method to ensure the proper storage, approval, use, and supervision of the raised funds, adhering to relevant laws and regulations [5][9] - The company has signed tripartite and quadripartite supervision agreements with banks and securities firms to ensure compliance in the management of the raised funds [7][8] Project Updates - The company has not made any changes to the fundraising projects from both the 2021 IPO and the 2022 targeted issuance [10][11] - The company has approved the addition of products such as L-Valine and Inositol to the annual production of 50,000 tons of bio-based succinic acid and bio-based product raw material production base construction project [9][12]

Core Viewpoint - The company is actively implementing its "Quality Improvement and Efficiency Enhancement" action plan for 2025, focusing on enhancing operational management, core competitiveness, and profitability in the biotechnology sector [1][2][3] Group 1: Business Development and Financial Performance - The company achieved total operating revenue of 1,489.16 million yuan, representing a year-on-year growth of 46.54%, with net profit attributable to shareholders reaching 114.89 million yuan, showing a quarter-on-quarter increase [1] - The company is focusing on biomanufacturing and applying successful production experiences to accelerate the industrialization of high-quality technological achievements, thereby enriching its product variety and enhancing the value of its industrial chain [1][2] Group 2: Product and Resource Optimization - The company is increasing R&D investment in new products, establishing a multi-dimensional product system that includes amino acids, vitamins, and bio-based new material monomers [2] - The company is enhancing the production capacity of L-valine and inositol by optimizing existing facilities and implementing flexible production technologies [2] Group 3: Internationalization and Brand Influence - The company is deepening its international development strategy, collaborating with Fortune 500 companies and industry leaders to expand into international markets and enhance its service capabilities [2][3] Group 4: R&D and Innovation - The company is committed to increasing R&D investment, with R&D expenses amounting to 68.67 million yuan, an increase of 8.40% year-on-year, and has a total of 512 patent applications [3][4] - The company emphasizes the integration of independent R&D and industry-academia collaboration to maintain technological leadership in the industry [4] Group 5: Corporate Governance and Investor Relations - The company has established a governance structure that ensures clear responsibilities and coordinated operations among its various governing bodies [4] - The company prioritizes high-quality information disclosure and investor communication, utilizing multiple channels to engage with investors and respond to their concerns [5] Group 6: Sustainable Development and ESG Commitment - The company adheres to a sustainable development strategy, focusing on green manufacturing and low-carbon initiatives, and has published its ESG report to showcase its commitment to environmental and social governance [6] - The company aims to optimize resource utilization and reduce reliance on traditional energy sources while enhancing operational efficiency [6] Group 7: Future Outlook and Continuous Improvement - The company will continue to evaluate the execution of its action plan and expand its product matrix to enhance core competitiveness and profitability [6][7]

安徽华恒生物科技股份有限公司（以下简称"公司"）为积极贯彻落实科创 板上市公司"提质增效重回报"专项行动，践行"发展生物技术，服务生命健 康"的使命，持续提升公司经营管理水平，不断提高公司核心竞争力和盈利能 力。2025 年上半年，公司行动方案主要举措的落实（进展）及成效情况具体如 下： 一、聚焦生物制造，发展新质生产力 安徽华恒生物科技股份有限公司 关于公司 2025 年度"提质增效重回报"行动方案的 半年度评估报告 四、加大研发创新投入，促进提升新质生产力 报告期内，公司持续聚焦生物制造，发展新质生产力，将生物制造领域的 成功生产经验应用到其他产品当中，加速更多优质科技成果的产业化落地进程， 不断丰富产品品种，发挥产品间的产业链价值，实现公司的长足稳定发展。公 司投资建设的人工智能驱动生物制造研发及中试示范基地，采用先进的微生物 发酵技术，结合人工智能精准控制发酵过程，引入自动化设备和控制系统，有 助于实现生产过程的实时监控和优化，提高产品产量和质量，打通从实验室小 试到工业级生产的技术瓶颈。报告期内，公司实现营业总收入为 148,916.05 万 元，同比增长 46.54%；归属于上市公司股东的净利润为 ...

证券代码:688639 证券简称:华恒生物 公告编号:2025-033 安徽华恒生物科技股份有限公司 2025 年半年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据上海证券交易所《上海证券交易所科创板上市公司自律监管指引第1 号——规范运作》的规定，现将安徽华恒生物科技股份有限公司（以下简称 "本公司"或"公司"）2025年半年度募集资金存放与实际使用情况报告如下： 一、募集资金基本情况 （一）2021年首次公开发行股票募集资金情况 1、实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于同意安徽华恒生物科技股份有限公司首 次公开发行股票注册的批复》（证监许可[2021]923号文）核准，公司于2021年 4月向社会公开发行人民币普通股（A股）2,700.00万股，每股发行价为23.16元， 应募集资金总额为人民币62,532.00万元，根据有关规定扣除发行费用6,606.12万 元后，实际募集资金金额为55,925.88万元。该募集资金已于2021年4月到账。上 ...

证券代码：688639 证券简称：华恒生物 公告编号：2025-032 安徽华恒生物科技股份有限公司 第四届监事会第十七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 安徽华恒生物科技股份有限公司（以下简称"公司"）第四届监事会第十七 次会议于 2025 年 8 月 27 日在公司会议室以现场结合通讯方式召开。本次会议应 到监事 3 人，实到监事 3 人。会议通知已于 2025 年 8 月 15 日以专人递送方式送 达全体监事。会议由监事会主席刘洋召集和主持。本次会议的召集、召开符合《中 华人民共和国公司法》和《公司章程》的有关规定。 二、监事会会议审议情况 经与会监事审议，议案表决结果如下： （一） 审议通过《关于公司 2025 年半年度报告及摘要的议案》 监事会认为：公司 2025 年半年度报告及其摘要内容真实、准确、完整，无 虚假记载、误导性陈述或者重大遗漏，2025 年半年度报告及其摘要的编制、审 核以及董事会的审议程序符合法律法规、公司章程等相关规定，内容与格式符合 相关规 ...

安徽华恒生物科技股份有限公司 2025 年半年度报告 1 / 209 安徽华恒生物科技股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真 实性、准确性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 二、 重大风险提示 本报告第三节"管理层讨论与分析"之四"风险因素"已进行了详细的阐述与揭示，敬请查 阅。 三、 公司全体董事出席董事会会议。 安徽华恒生物科技股份有限公司2025 年半年度报告 公司代码：688639 公司简称：华恒生物 五、 公司负责人郭恒华、主管会计工作负责人樊义及会计机构负责人（会计主管人 员）朱修发声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 不适用 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 四、 本半年度报告未经审计。 十、 是否存在违反规定决策程序对外提供担保的情况 否 十一、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和 完整性 ...